Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC, Brodermann MH, Blakeney IJ, Mahmood S, Sachchithanantham S, Ravichandran S, Law S, Lachmann HJ, Whelan CJ, Popat R, Rabin N, Yong K, Kyriakou C, Shah R, Cheesman S, Worthington S, Hawkins P, Gillmore JD, Wechalekar AD.
Cohen OC, et al. Among authors: sachchithanantham s.
Amyloid. 2020 Sep;27(3):200-205. doi: 10.1080/13506129.2020.1765768. Epub 2020 May 15.
Amyloid. 2020.
PMID: 32408823
Clinical Trial.